XOMA Royalty (NASDAQ:XOMA) Shares Pass Above Two Hundred Day Moving Average – What’s Next?

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $31.18 and traded as high as $41.75. XOMA Royalty shares last traded at $41.71, with a volume of 78,306 shares.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Lucid Cap Mkts lowered XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. Benchmark lowered XOMA Royalty from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. Zacks Research raised XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. Finally, TD Cowen raised XOMA Royalty to a “hold” rating in a report on Friday, February 13th. One equities research analyst has rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, XOMA Royalty has an average rating of “Hold” and an average target price of $53.75.

XOMA Royalty Price Performance

The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.96. The stock has a market cap of $523.09 million, a price-to-earnings ratio of 26.57 and a beta of 0.90. The stock has a fifty day moving average of $37.88 and a two-hundred day moving average of $31.18.

XOMA Royalty (NASDAQ:XOMA) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.02). The firm had revenue of $12.32 million during the quarter, compared to analyst estimates of $13.91 million. XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. On average, equities research analysts anticipate that XOMA Royalty Corporation will post 0.9 earnings per share for the current year.

Institutional Trading of XOMA Royalty

Several large investors have recently bought and sold shares of XOMA. Woodline Partners LP grew its holdings in XOMA Royalty by 7.9% in the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock valued at $3,359,000 after purchasing an additional 12,284 shares during the last quarter. Geode Capital Management LLC grew its holdings in XOMA Royalty by 9.1% in the second quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after purchasing an additional 16,929 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 543 shares during the last quarter. Rhumbline Advisers grew its holdings in XOMA Royalty by 18.0% in the second quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock valued at $334,000 after purchasing an additional 2,019 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in XOMA Royalty by 12.2% in the second quarter. Marshall Wace LLP now owns 16,308 shares of the biotechnology company’s stock valued at $411,000 after purchasing an additional 1,775 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.